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RNA interference is a mechanism for controlling normal gene expression which has recently begun to be 
employed as a potential therapeutic agent for a wide range of disorders, including cancer, infectious diseases and 
metabolic disorders. Clinical trials with RNA interference have begun. However, challenges such as off-target 
effects, toxicity and safe delivery methods have to be overcome before RNA interference can be considered as a 
conventional drug. So, if RNA interference is to be used therapeutically, we should perform a risk-benefit 
analysis. It is ethically relevant to perform a risk-benefit analysis since ethical obligations about not inflicting 
harm and promoting good are generally accepted. But the ethical issues in RNA interference therapeutics not 
only include a risk-benefit analysis, but also considerations about respecting the autonomy of the patient and 
considerations about justice with regard to the inclusion criteria for participation in clinical trials and health care 
allocation. RNA interference is considered a new and promising therapeutic approach, but the ethical issues of 
this method have not been greatly discussed, so this article analyses these issues using the bioethical theory of 
principles of the American bioethicists, Tom L. Beauchamp and James F. Childress. 
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1.  Introduction 
RNA interference (RNAi) is a specific and 
efficient natural mechanism for controlling gene 
expression. In recent years, RNAi has become a 
powerful tool for probing gene functions and 
rationalising drug design. It has been employed as a 
potential therapeutic agent for combating a wide range 
of disorders, including cancer, infectious diseases and 
metabolic disorders. A lot of knowledge about RNAi 
has been accumulated since its discovery in 1998 [1] 
and findings such as the specific and efficient 
knock-down of the oncogene K-ras [2] have 
emphasised the potential of RNAi in clinical 
applications. 
  Clinical trials with RNAi have now begun, but 
major obstacles, such as off-target effects, toxicity and 
unsafe delivery methods, have to be overcome before 
RNAi can be considered as a conventional drug. 
Generally, the success of the therapeutic use of RNAi 
relies on three conditions: 1) lack of toxicity, 2) 
specificity of silencing effects and 3) efficacy in vitro 
and  in vivo [ 3 - 6 ] .  S o  i f  R N A i  i s  t o  b e  u s e d  
therapeutically one should weigh the possible harms 
against the possible benefits of this method (perform a 
risk-benefit analysis). The terms harms and benefits 
are ethically relevant concepts since ethical obligations 
or principles about not inflicting harm 
(nonmaleficence) and promoting good (beneficence) 
are generally accepted [7]. The ethical principles of 
nonmaleficence and beneficence form part of several 
different ethical theories. For instance, they are the 
foundation of the utilitarian theory, which says that 
ethically right actions are those that favour the greatest 
good for the greatest number [8]. Another example is 
the Hippocratic Oath, which expresses an obligation of 
beneficence and an obligation of nonmaleficence: “I 
will use treatment to help the sick according to my 
ability and judgment, but I will never use it to injure or 
wrong them” [7]. So clearly risk-benefit analysis is an 
ethical issue. However, according to the American 
bioethicists Tom L. Beauchamp and James F. Childress 
[7], ethical issues of biomedicine include not only 
weighing the possible harms against the possible 
benefits (risk-benefit analysis), but also considerations 
about respecting the autonomy of the patient or 
human subject and considerations about justice with 
regard to health care allocation. Beauchamp & 
Childress argue that the four essential ethical 
principles in biomedicine are the principles of 
nonmaleficence, beneficence, respect for autonomy Int. J. Med. Sci. 2008, 5 
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and justice. Since RNAi is considered to be a new and 
promising therapeutic approach, and because the 
ethical issues of this approach have not been greatly 
discussed, this article analyses these issues using the 
ethical principles of Beauchamp & Childress. Firstly, 
we provide a brief introduction to the RNAi 
mechanisms and the movement of RNAi from 
laboratory studies to clinical trials. Secondly, we 
describe the ethically relevant features of RNAi 
therapeutics that are important for a risk-benefit 
analysis. Lastly, we focus on considerations about 
respecting the autonomy of the patient or human 
subject and considerations about justice with regard to 
inclusion criteria for participation in clinical trials and 
health care allocation.  
2. RNAi Therapeutics Moving from 
Laboratory Studies to Clinical Trials 
Background about the RNAi mechanisms 
RNAi is a conserved biological mechanism 
controlling normal gene expression. The silencing 
mechanisms occur at the levels of transcription, 
post-transcription and translation. RNAi can also 
cause augmentation of gene expression due to direct 
effects on the translation [9]. RNAi is also regarded as 
a natural defence mechanism against mobile 
endogenous transposons and invasion by exogenous 
viruses which have dsRNA as an intermediate 
product. With this defence mechanism, organisms 
maintain genetic integrity and hinder infection [10].  
Research into RNAi is a fast-developing field and 
a lot of knowledge has accumulated since its discovery 
in 1998. In the following, we summarise current 
knowledge about the RNAi processes. 
Post-transcriptional gene silencing 
  At the initiator step of post-transcriptional gene 
silencing, long double-stranded RNA (dsRNA), which 
can be produced by endogenous genes, invading 
viruses, transposons or experimental transgenes, are 
cleaved by the enzyme Dicer, which generates 21-23 
nucleotide (nt) duplex RNAs with overhanging 3’ 
ends, called small interfering RNAs (siRNAs). Next, 
siRNAs are incorporated into the RNA-induced 
silencing complex (RISC), which directs RISC to 
recognise target mRNAs and cleave them with 
complementary sequences to the siRNA [11]. 
Translational gene silencing 
RNAi gene inhibition at the level of translation 
also involves Dicer, which produces 21-to-23-nt-long 
micro RNAs (miRNAs) synthesised from 60-to-70-nt 
stem-loop precursor miRNAs (pre-miRNAs). The 
complex of the activated RISC and miRNA binds the 
3’UTR of specific mRNAs, which triggers cleavage by 
perfect base-pairing recognition or translational 
repression by partial base-pairing recognition [11]. 
Transcriptional gene silencing and gene activation 
Studies have shown that the RNAi machinery is 
located in the cytoplasm and therefore acts on mature 
rather than nuclear precursor mRNA [12]. However, 
promoter-directed siRNAs can also mediate 
transcriptional gene silencing in mammalian cells 
when delivered to the nucleus [13, 14]. This silencing is 
associated with DNA methylation of the targeted 
sequence [13, 15]. Moreover, miRNAs complementary 
to promoter regions have been observed using the 
RNAi pathway to activate genes in the nucleus [16, 17]. 
In contrast to silencing, which is triggered within 
hours and ceases after about seven days, activation 
takes days to appear but can last for weeks. The 
mechanism behind this activation is not known.  
Pre-clinical studies 
 Since the obligation not to inflict harm implies an 
obligation to test a potential drug in animal models 
before it is delivered to humans, pharmaceutical 
companies conduct extensive pre-clinical studies. 
These involve studies in test tubes, cell cultures and 
animal models to obtain preliminary efficacy, toxicity 
and pharmacokinetic information and to help decide 
w h e t h e r  i t  i s  w o r t h w h i l e  t o  g o  a h e a d  w i t h  f u r t h e r  
testing. Below we present some examples of 
pre-clinical studies in mouse models to test RNAi 
against cancer.   
Cancer animal models  
 Animal models are widely used to investigate the 
therapeutic efficiency of RNAi.  In vivo utilisation of 
siRNA was effectively performed by targeting the 
colorectal cancer-associated gene beta-catenin. 
Decreased proliferation and diminished invasiveness 
were observed following siRNA-mediated silencing of 
this gene in human colon cancer cells. Additionally, 
when treated cancer cells were placed in a nude 
mouse, prolonged survival was seen compared with 
mice receiving unmanipulated tumours [18]. Similarly, 
silencing the oncogene H-ras led to inhibition of in vivo 
tumour growth of human ovarian cancer in a SCID 
mouse model [19].   
 To study the effects of inhibition of the oncogenic 
K-ras expression on the tumourigenic phenotype of 
human cancer cells, Brummelkamp et al. [2] targeted 
the expression of the endogenous mutant K-ras V12 
allele in a human pancreatic cell line and observed an 
efficient inhibition of K-ras V12 in the cancer cells. 
Analysis showed that the siRNAs were sufficiently 
selective to distinguish between the wild type and the 
K-ras V12 allele. The oncogenic cells expressing 
siRNAs against K-ras V12 lost their ability to grow Int. J. Med. Sci. 2008, 5 
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independent of anchorage when plated in semisolid 
media, and they lost their ability to form tumours in 
nude mice when transplanted. The experiments 
performed by Brummelkamp et al. [2] demonstrate that 
it is possible selectively to knock down just the 
mutated version of a gene. This gives rise to optimism 
about the cancer treatment applications of RNAi, for it 
is possible to design a sequence-specific therapy, 
which only blocks the expression of an oncogene and 
not the wild type allele.  
Clinical trials for RNAi therapies 
  Clinical trials with RNAi therapies have already 
started (Table 1). One of the first applications of RNAi 
in clinical trials is siRNA for age-related macular 
degeneration (AMD). AMD is caused by the abnormal 
growth of blood vessels behind the retina. The 
treatment strategy is inhibition of the vascular 
endothelial growth factor pathway by siRNA. These 
RNAi therapies are designed to be administered 
directly to the sites of disease in the eye [3]. However, 
recently new findings call into question the premise 
behind these clinical trials. Studies in mouse models 
suggest that the anti-angiogenesis effect is not caused 
by RNAi, but instead induced in a non-specific manner 
by RNAs that vary in sequence1 [20]. 
Table 1. RNAi based therapies [19]. 
Indication  Company  RNAi platform (target)  Clinical stage
Acuity  Modified siRNA (VEGFR)  Phase II 
Sirna  Modified siRNA (VEGF)  Phase I/II 
Wet AMD 
Alnylam siRNA  Phase  I 
Infectious 
disease 
Alnylam  siRNA for RSV (viral gene)  Phase I 
  
  Clinical trials for RNAi therapies belong to the 
category of ‘treatment trials’ 2 since new drugs are 
being tested. Often these trials are designed as 
randomised, double-blind and placebo-controlled.   
Phases    
 Clinical trials involving new drugs are commonly 
classified into four phases. Each phase of the drug 
approval process is treated as a separate clinical trial. 
The drug-development process will normally proceed 
through all four phases over many years. If the drug 
                                                      
1 It may be ethically problematic to continue these trials without 
reconsiderations, since the basis for the the study and the informed 
consents given has changed. 
2 Clinical trials are often divided into 1) prevention trials, which 
test new approaches believed to lower the risk of developing a 
certain disease, 2) screening trials, which study ways of detecting a 
certain disease earlier, 3) diagnostic trials, which study tests or 
procedures that could be used to identify a certain disease more 
accurately, and 4) treatment trials, which are conducted with 
patients suffering from a certain disease. They are designed to 
answer specific questions and evaluate the effectiveness of a new 
treatment such as a new drug [21]. 
successfully passes through phases I, II and III, it will 
usually be approved by the national regulatory 
authority for use in the general population. Phase IV 
consists of post-approval studies involving the safety 
surveillance of a drug after it receives marketing 
approval. The safety surveillance is designed to detect 
any rare or long-term adverse effects over a much 
larger patient population and longer time period than 
was possible during phases I-III clinical trials [21].   
Ethical considerations of beneficence and nonmaleficence 
regarding clinical trials 
  Generally, participants in a clinical trial benefit 
from having access to promising new approaches that 
are often not available outside the clinical trial setting, 
and they receive regular and careful medical attention 
from a professional research team. Furthermore, the 
participants may be the first to benefit from the new 
method under study. Lastly, the results from the study 
may help others in the future.  
  However, participating in a clinical trial also 
entails some possible risks. For example, new drugs or 
procedures under study are not always better than the 
standard care to which they are being compared. The 
new treatments may have side effects or risks that 
physicians do not expect or that are worse than those 
resulting from standard care. Furthermore, 
participants in randomised trials will not be able to 
choose the approach they receive and may be required 
to make more visits to the physician than they would if 
they were not in the clinical trial [21]. 
3. Risk-Benefit Analysis of RNA 
Interference-based Therapies 
According to Beauchamp & Childress [22] the 
evaluation of risk in relation to probable benefit is 
often labelled risk-benefit analysis. They say that the 
term risk refers to a possible future harm, where harm 
is defined as “a setback to interests, particularly in life, 
health, and welfare” [7]. Statements of risk are both 
descriptive and evaluative. They are descriptive 
inasmuch as they state the probability that harmful 
events will occur, and they are evaluative inasmuch as 
they attach a value to the occurrence or prevention of 
the events [7]. In the field of biomedicine, the term 
benefit commonly refers to something of positive value, 
such as life or health. The risk-benefit relationship may 
be conceived in terms of the ratio between the 
probability and magnitude of an anticipated benefit 
and the probability and magnitude of an anticipated 
harm. Use of the terms risk and benefit necessarily 
involves evaluation. Values determine both what will 
count as harms and benefits and how much weight 
particular harms and benefits will have in the 
risk-benefit calculation [7]. The terms harm and Int. J. Med. Sci. 2008, 5 
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benefit, as defined above, are ethically relevant 
concepts, since ethical obligations or principles about 
not inflicting harm (nonmaleficence) and promoting 
good (beneficence) are generally accepted [7]. 
According to Beauchamp & Childress [7], the 
weighing of the general ethical principles of 
nonmaleficence and beneficence is not symmetrical, 
since our obligation not to inflict evil or harm 
(nonmaleficence) is more stringent than our obligation 
to prevent and remove evil and harm or to do and 
promote good (beneficence). Our beneficence 
obligation implies taking action (positive steps) to help 
prevent harm, remove harm and promote good, 
whereas our nonmaleficence obligation only implies 
intentionally refraining from actions that cause harm. 
So, according to Beauchamp & Childress, possible 
harms associated with potential therapies are given 
more weight in a risk-benefit analysis. 
  To minimise the harm done to patients, medical 
applications of RNAi require that RNAi is tested in 
clinical trials, in which the possible risks and possible 
benefits of potential treatments are evaluated. It is 
important to identify the ethically relevant features of 
RNAi which are central for the risk-benefit analysis. 
These ethical features include siRNA delivery and the 
specificity of silencing effects. 
siRNA Delivery 
 The challenge of siRNA delivery is to overcome 
extracellular and intracellular barriers to achieve 
efficient target cell delivery. Previous studies have 
shown that siRNA and DNA have difficulty in 
circulating in the bloodstream, passing across cellular 
membranes, and escaping from endosomal-lysosomal 
compartments [23]. Viral and non-viral carrier systems 
have been developed to increase the delivery of 
siRNA. For instance, the use of viral vectors based on 
retrovirus, adenovirus or adeno-associated viruses 
(AAV) to deliver siRNAs has shown effective gene 
silencing in vitro and in vivo [24-26]. Below we describe 
the use of retroviral vectors in more detail.  
Retroviral delivery  
  Retroviruses have some unique properties that 
make them attractive to biomedical research as tools 
for gene transfer. Retroviruses are a group of 
enveloped RNA viruses that replicate via a DNA 
intermediate that becomes integrated as a provirus 
into the genome of the host. Integration of the provirus 
is an advantage, since it results in the stable expression 
of the genes delivered in the cell and its daughter cells. 
Using retroviral siRNA expression vectors also allows 
the addition of regulatory elements to the promoter 
region so that tissue-specific silencing occurs [27]. 
Retroviral vectors have been constructed to express 
siRNAs in order to obtain a persistent gene knock 
down [2, 28, 29]. However, one of the main drawbacks 
of retroviral gene therapy trials is insertional 
mutagenesis. Integrating a retroviral genome into 
actively transcribed genes and/or protooncogenes 
may lead to malignancies, as in infants treated for 
X-linked severe combined immunodeficiency (X-SCID) 
with retroviral gene therapy [30-32]. But it should be 
remembered that disease-specific issues may have 
played an important role in the development of these 
malignancies. In this specific case, to avoid insertional 
mutagenesis a small number of cells can be transduced 
ex vivo and an insertion site analysis performed before 
they are infused back into the patient. Moreover, when 
evaluating whether the beneficence of the gene 
therapy application counterbalances the risks, the 
severity of the disease should be considered. SCID-X1 
is often fatal if not treated, and the only alternative 
therapy available is unrelated or haploidentical 
hematopoietic stem cell transplantation, which offers 
lower correction rates with higher morbidity and 
mortality than gene therapy [31]. It is generally agreed 
that the benefits still outweigh the dangers given that 
there is no known case of vector-triggered cancer other 
than the SCID-X1 patients [33]. Brummelkamp et al. [2], 
who have performed specific downregulation of K-ras 
V12 by retroviral-delivered siRNAs, suggest that “the 
selective downregulation of only the mutant version of 
a gene allows for highly specific effects on tumour 
cells, while leaving the normal cells untouched. This 
feature greatly reduces the need to design viral vectors 
with tumour-specific infection and/or expression”. 
However, when considering the risk of insertional 
mutagenesis, non-viral delivery systems must also be 
considered. 
Nanoparticle delivery  
 Non-viral  delivery  systems, using for instance 
cationic liposomes and polycation-based carriers such 
as polyethylenimine (PEI), have been developed for 
siRNAs. These carriers have been used for in vivo 
siRNA delivery and gene silencing after intravenous or 
intranasal administration. However, these systems 
exhibit in vivo toxicity and activate the immune system 
[6, 24, 34-37]. This has led to a lot of effort being made 
to develop efficient carrier materials that are non-toxic, 
biocompatible and biodegradable. Chitosan, a 
naturally occurring cationic polysaccharide, is such a 
material. 
  Chitosan has been widely used in drug delivery 
systems, especially for DNA-mediated gene therapy. 
The positively charged amines of chitosan allow 
electrostatic interaction with phosphate-bearing 
nucleic acids to form polyelectrolyte complexes. 
Furthermore, the protonated amine groups allow Int. J. Med. Sci. 2008, 5 
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transport across cellular membranes and subsequent 
endocytosis into cells. It has been shown that a 
chitosan/siRNA nanoparticle delivery system silences 
genes in vitro and in vivo. Moreover, chitosan has been 
shown to be biocompatible, non-inflammatory, 
non-toxic and biodegradable [24]. These facts show the 
importance of considering chitosan/siRNA 
nanoparticles as delivery systems in RNAi 
therapeutics.   
Off-target effects 
  When considering using siRNAs as therapeutic 
drugs, it is also important to investigate the sequence 
specificity of RNAi and the risk of off-target effects. 
For instance, it is vital to ensure that only the targeted 
mRNA is degraded because otherwise essential genes 
may be blocked.  
 It seems that siRNAs can have off-target effects as 
a result of one of three mechanisms: (1) Since both 
shRNAs (pre-siRNAs/pre-miRNAs) and siRNAs 
contain strings of dsRNA, they can activate 
non-specific cellular innate immune responses such as 
the interferon response. (2) Transfected or expressed 
siRNAs might have other non-specific effects. For 
example, artificial siRNAs or shRNAs could saturate 
the cell’s RNAi machinery and thereby inhibit the 
function of endogenous miRNAs. (3) Although mature 
siRNAs are designed to be fully complementary to a 
single mRNA transcript, they may inadvertently show 
considerable complementarities to other non-target 
mRNAs [38]. 
Interferon response 
 Studies have shown that an interferon response is 
induced by dsRNAs more than 30 bp in length, but 
also perfect dsRNAs as small as 11 bp in length can 
produce a weak induction [38]. However, steps can be 
taken to minimise this problem. For instance, since 
non-specific off-target effects, including activation of 
the interferon response, are more likely when high 
levels of an siRNA are used, it is important to transfect 
the minimum amount of the siRNA duplex that gives 
rise to a specific RNAi response [39]. It is possible to 
measure a possible interferon response by analysing 
the level of expression of an interferon-response gene, 
such as oligoadenylate synthase-1 (OAS1), by 
northern-blot or reverse-transcriptase PCR analysis 
[40, 41]. 
Saturation of the RNA interference machinery 
 In addition to the effects of the interferon system, 
the introduced siRNAs can reportedly saturate the 
cellular RNAi machinery and thus inhibit the function 
o f  e n d o g e n o u s  m i R N A s  a n d  g i v e  r i s e  t o  t o x i c  
non-specific effects. These non-specific effects again 
mandate the use of the lowest effective level of 
artificial siRNAs in transfection experiments [38].  
Changed expression of off-target genes 
 There are conflicting reports about the specificity 
of the sequence match between the siRNA and the 
target mRNA required to achieve specific gene 
silencing. Elbashir et al. [42] found that a single 
mismatch between the siRNA and the target mRNA 
hinders RNAi activity. Contrary to this, Boutla et al. 
[43] reported that a mutated siRNA with a single 
centrally located mismatch relative to the mRNA 
target sequence retained substantial silencing in the 
fruit fly Drosophila. Studies have shown that siRNAs 
generally tolerate mutations in the 5’end, while the 
3’end exhibits low tolerance [11, 44-47]. These results 
support the proposed biological function of RNAi as a 
defence system against viruses, since the tolerance of 
single mismatches should make viral escape more 
difficult [44]. The fact that siRNAs are sequence 
specific to different degrees suggests that the tolerance 
for mutations is at least partly target-sequence 
dependent.  
  If RNAi is used as a therapeutic drug, the 
above-mentioned studies indicate a need to investigate 
whether off-target genes with partly sequence 
similarity to the siRNA also become silenced by the 
RNAi mechanism. Genes with partly sequence 
similarity to the siRNA can be found by a BLAST 
search (NCBI database) against human EST libraries. 
The monitoring of off-target gene expression must be 
performed at both the mRNA level and the protein 
level, making sure that the siRNA does not function as 
a miRNA and repress translation of off-target mRNAs. 
 But off-target silencing is not the only thing that 
needs to be investigated – off-target up-regulations 
have also been demonstrated. A microarray study by 
Bakalova [48] shows that silencing one oncogene by 
RNAi (encoding BCR-ABL fusion protein in chronic 
myelogenous leukaemia) triggers an overexpression of 
other ‘sleeping’ oncogenes, antiapoptotic genes and 
factors, preserving immortalisation of 
BCR-ABL-positive leukaemia cells. 
  Since non-specific off-target effects, including 
activation of the interferon response and saturation of 
the RNAi machinery, are more likely when high levels 
of a siRNA are used, it is important to include an 
inducible promoter to control the transcription level of 
siRNAs.    
4. Ethical Analysis  
The four principles of biomedical ethics 
  Above, we have described the ethically relevant 
features of RNAi therapeutics which are important for 
the risk-benefit analysis. However, according to Int. J. Med. Sci. 2008, 5 
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Beauchamp & Childress [7] ethical issues of 
biomedicine not only include the balance of the 
possible harms and the possible benefits (risk-benefit 
analysis), but also considerations about respecting the 
autonomy of the patient or human subject and 
considerations about justice with regard to inclusion 
criteria for participation in clinical trials and health 
care allocation. They argue that the four ethical 
principles of nonmaleficence, beneficence, respect for 
autonomy and justice are central to and play a vital 
role in biomedicine. They first published their 
bioethical theory of principles in 1979, in the book 
Principles of Biomedical Ethics. This book has been 
published in many revised and expanded editions [7]. 
Beauchamp & Childress’ bioethical theory is one of the 
most influential bioethical theories and much research 
has been carried out by ethicists to reformulate the 
principles and make them yet more adequate for use in 
the practice of biomedicine. In Figure 1, we present a 
brief formulation of the four principles of biomedical 
ethics.  
 
 
Figure 1. The four principles of biomedical ethics. A brief formulation of the four bioethical principles of Beauchamp & Childress 
[7]. 
 
  Beauchamp & Childress stress that no one 
principle ranks higher than the others. Which 
principles should be given most weight depends on 
the context of the given situation. Beauchamp & 
Childress regard the four principles as prima facie 
binding, i.e. they must be fulfilled, unless they conflict 
on a particular occasion with an equal principle. 
Beauchamp & Childress write: “Some acts are at once 
prima facie wrong and prima facie right, because two 
or more norms conflict in the circumstances. Agents 
must then determine what they ought to do by finding 
an actual or overriding (in contrast to prima facie) 
o b l i g a t i o n ”  [ 7 ] .  T h u s  t h e  a g e n t s  m u s t  f i n d  t h e  b e s t  
balance of right and wrong by determining their actual Int. J. Med. Sci. 2008, 5 
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obligations in such situations through a study of the 
respective weights of the competing prima facie 
obligations (the relative weights of all competing 
prima facie norms) [7].   
  Beauchamp & Childress [7] believe that the 
principles find support across different cultures. They 
claim that the principles are part of a cross-cultural 
common morality and that in all cultures people who 
are serious about moral conduct accept the norms of 
this common morality [7]. But even though these 
principles are generally acknowledged, this does not 
mean that there is consensus about what is good and 
bad. Interesting discussions occur when the principles 
are to be interpreted, specified and balanced in specific 
historical, social and political contexts.  
 Beauchamp [50] claims that the usefulness of the 
four principles can be tested empirically and that it can 
be determined whether they are part of a cross-cultural 
common morality. But he does not present any 
empirical data to support this position; however, he 
does invite the design of an empirical research study to 
investigate the question. A Danish empirical study 
shows that the four bioethical principles of Beauchamp 
& Childress are reflected in the daily work of Danish 
oncology physicians and Danish molecular biologists 
[51-54]. 
  We have now shown which features of RNAi 
therapies are important for a risk-benefit analysis. 
Below, we want to highlight considerations about 
respect for the autonomy of the patient or human 
subject and considerations of justice with regard to 
inclusion criteria for participation in clinical trials and 
allocation of health care services. 
Respect for autonomy  
  Human subjects agree to participate in clinical 
trials through informed consent. The information 
given includes details about standard treatment and 
about what is involved in the trial, such as the purpose 
of the study, the tests, and the possible risks and 
benefits. Subjects or patients can leave the study at any 
time before the study starts, during the study, or 
during the follow-up period [21]. The ethical principle 
governing informed consent is the principle of respect 
for the autonomy of the human subject or patient. This 
principle only applies to people able to act 
autonomously (otherwise they are protected by the 
principles of nonmaleficence and beneficence) [7]. 
When analysing the role of the principle of respect for 
autonomy regarding RNAi gene therapy trials, it is 
important to consider the risk of generating 
infection-competent viruses from virus vectors. These 
replication competent viruses could infect 
non-consenting people. Furthermore, it is important to 
consider the risk of introducing genetic changes in 
germ line cells. This could be seen as tantamount to a 
clinical experiment on non-consenting subjects 
belonging to the future generations affected by such 
changes. Considerations about the risks of generating 
replication-competent viruses and the risk of 
introducing genetic changes in germ line cells are also 
part of risk-benefit analysis.   
Justice considerations 
  Unlike the three other principles, justice is not 
one single principle, but rather a concept that can be 
determined in various ways. Consequently, 
Beauchamp & Childress do not present one principle 
of justice. Two basic things are more or less given 
when discussing justice. First, justice – as Aristotle put 
it – always consists in treating like cases equally. And 
second, in the context of health care, we are dealing 
with distributive justice, in which justice is a principle 
for distributing goods and burdens among individuals 
in a morally right way. This raises two important 
questions: What are like cases and what does it mean 
to treat them equally? And what is a morally right 
distribution of goods and burdens? 
  On the latter question, Beauchamp & Childress 
[7] mention the various answers given by the most 
prominent theories of justice. These are 1) 
utilitarianism, which regards justice as the 
maximisation of utility; 2) libertarianism, in which a 
just society protects rights of property and liberty and 
just distribution occurs according to free market forces; 
3) egalitarianism, in which inequalities are only 
allowed if they benefit the least advantaged; and 4) 
communitarianism, which sees justice determined by 
the values of a given community. Beauchamp & 
Childress do not adopt just one of these theories of 
justice but rather try to combine them. In a way, they 
treat the theories of justice as they think the four 
principles should be treated when applied: theories of 
justice should be specified and balanced with the goal 
of reaching a coherent health care system. 
  The various theories of justice differ in defining 
the good that a health care system distributes. 
Utilitarianism, of course, regards utility as that good. 
This is not the view of Beauchamp & Childress – they 
tend to adopt the egalitarian concept of good in John 
Rawls’ theory of justice. Here, justice means fair 
opportunity: the goods to be distributed are 
compensations for disadvantages caused by the 
natural or social ‘lottery’. Thus fair opportunity means 
that a person born disabled should receive special 
services, and a child from a poor family should have 
the same education as other children. Notice, however, 
that ‘same’ does not mean ‘identical’: in the case of 
education, ‘same’ means according to intelligence and 
other properties. In the case of health care ‘same’ could Int. J. Med. Sci. 2008, 5 
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mean according to need, i.e. to the seriousness and 
urgency of the suffering [7]. 
  Beauchamp & Childress [7] think that a fair 
health care system includes two strategies for health 
care allocation: 1) a utilitarian approach emphasising 
maximal benefit to patients and society, and 2) an 
egalitarian strategy that emphasises the equal worth of 
people and fair opportunity. Beauchamp & Childress 
defend the egalitarian principle that all citizens have a 
right to a decent minimum of health resources. This 
entails a two-tiered system with social coverage for 
basic and catastrophic health needs, and voluntary 
private coverage for other health needs, such as better 
service, luxury hospital rooms, etc. [7].  
 But the question arises whether people can forfeit 
this right to a decent minimum of health care. 
Beauchamp & Childress [7] believe that in some cases 
people forfeit their right if they are personally 
responsible for their disease or illness, i.e. if the disease 
or illness results from personal activities that have 
been autonomous. They mention several conditions 
where personal responsibility should affect priorities. 
One example might be alcoholics who fail to seek 
effective treatment for alcoholism, suffer from 
alcohol-related end-stage liver failure, and need liver 
transplants. And there are several properties for which 
people are not responsible but which have often 
served unjustly as bases of distribution; these include 
gender, race, IQ, and national origin [7]. In contrast, 
Beauchamp & Childress defend the so-called Fair 
Opportunity Rule, which says “no persons should 
receive social benefits on the basis of undeserved 
advantageous properties (because no persons are 
responsible for having these properties) and that no 
persons should be denied social benefits on the basis of 
undeserved disadvantageous properties (because they 
also are not responsible for these properties)” [7].   
 Justice in health care is not, however, restricted to 
the health care system. It is also connected with 
rationing and prioritisation (what kinds of health 
services should be available) and selection (what 
groups of patients should be eligible for a given service 
and how to select in individual cases). In relation to 
these aspects, Beauchamp & Childress also defend a 
concept of justice that combines equality with utility in 
the way indicated. 
 We find Beauchamp & Childress’ perception of a 
fair distribution of healthcare convincing in several 
ways. However, we presuppose a healthcare system 
covering in principle all citizens without reference to 
age, health status, lifestyle, medical condition or 
employment status. Every person gets national health 
care, pays no charges for services, is free to choose a 
provider, and is eligible to receive the services covered, 
which among others include long-term and chronic 
care services3. Within this system, excluding people 
from social coverage because they suffer from a 
disease caused by personal autonomous activities is 
seen as unjust. If we now try to apply the principle of 
justice to RNAi-based treatments, three points are 
important.  
  (1) If these treatments turn out to be medically 
and economically efficient, there is no doubt that they 
should be included in the health services accessible to 
all.  
 (2) If we followed Beauchamp & Childress’ view 
o n  f a i r  d i s t r i b u t i o n  o f  h e a l t h  c a r e ,  i t  w o u l d  b e  
important to ask whether the disease results from 
personal activities and whether the patient is therefore 
personally responsible. In some cases, if the person is 
personally responsible, the treatment should not be 
covered by the public health care system but by private 
coverage. Since it is hoped that RNAi-based therapies 
can cure diverse diseases like cancer, infectious 
diseases and metabolic disorders, the evaluation of 
personal responsibility and social coverage of health 
c a r e  n e e d s  t o  b e  d o n e  o n  a  c a s e - b y - c a s e  b a s i s .  F o r  
instance, a patient may suffer from a cancer caused by 
cigarette smoking and seek RNAi therapy to combat 
this disease. In this case, the patient might be 
considered personally responsible for the cancer and 
have to finance the RNAi therapy themselves. 
However, first of all diseases often result from various 
factors such as genetic predisposition, personal 
activities, and social and environmental conditions, 
and it would be difficult to establish the respective 
roles of these factors. Secondly, we think it unjust to 
exclude patients suffering from diseases that they are 
personally responsible for from the public health care 
system.  
  (3) Justice considerations regarding RNAi 
therapies are not only important when these therapies 
are considered as conventional drugs; they are also 
important during the experimental phase in the 
development of these therapies. These justice 
considerations include inclusion criteria for 
participation in clinical trials. For instance, physicians 
may justifiably exclude from clinical trials people who 
suffer from other diseases that might obscure the 
research result [7]. Until the 1990s, ethical analysis of 
clinical trials focused on protecting research subjects 
                                                      
3 Beauchamp & Childress [22] suggest the Scandinavian health 
care systems as ideal way of organising health care delivery in the 
way indicated. However, these health care systems are currently 
under pressure and are undergoing a perceptible change. In 
Denmark, for instance, private hospitals and private health 
insurances now supplement the public system. 
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from harm, abuse and exploitation. The concern was 
about unfair distribution of burdens. However, in part 
because of the interest of patients with HIV/AIDS in 
gaining access to new experimental drugs, the focus 
shifted during the 1990s towards the benefits of 
therapeutic trials. As a result, justice in the form of fair 
access to research became as important as protection 
from exploitation [7]. This might also be the case with 
RNAi therapeutics. 
5. Conclusion 
  R e s e a r c h  i n  R N A i  t h e r a p e u t i c s  i s  a  f a s t  
developing field and a lot of knowledge about RNAi 
has accumulated since the mechanisms of RNAi were 
discovered in 1998. Clinical trials have already begun. 
We believe it is essential to discuss the ethical issues of 
RNAi therapies before these therapies are considered 
as conventional drugs. In this article, therefore, we 
provided an analysis of the ethically relevant features 
of RNAi therapies important for a risk-benefit analysis. 
These ethically relevant features include siRNA 
delivery and the specificity of silencing effects. For the 
future development of RNAi-based therapies we 
believe it is important to perform a risk-benefit 
analysis and to respect the autonomy of the human 
subject or patient by considering the risks of 
generating infection-competent viruses or introducing 
genetic changes in germ line cells. Furthermore, we 
think it is important to consider aspects of justice such 
as equal access vs. private acquisition, and a possible 
right to participate in clinical trials. 
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